Aptinyx to Participate at 10th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Aptinyx Inc. (Nasdaq: APTX) announced its participation in a virtual fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021, at 10:40 a.m. EST. The event will be webcast live and available for 30 days on the company’s website. Aptinyx is focused on developing therapies for brain and nervous system disorders, utilizing a unique mechanism to modulate NMDA receptors. The company has three clinical candidates targeting chronic pain, PTSD, and cognitive impairment linked to Parkinson’s disease.

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will participate in a virtual fireside chat at the 10^th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 10:40 a.m. EST.

A live webcast of the presentation will be available to view on the “Events and Presentations” page in the “Investors & Media” section of Aptinyx’s website at https://ir.aptinyx.com and will be archived on Aptinyx’s website for 30 days following the event.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson’s disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.

Source: Aptinyx Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005037/en/

FAQ

When will Aptinyx participate in the SVB Leerink Global Healthcare Conference?

Aptinyx will participate in the SVB Leerink Global Healthcare Conference on February 25, 2021, at 10:40 a.m. EST.

Where can I watch the Aptinyx presentation from the conference?

The presentation will be available via a live webcast on the 'Events and Presentations' page of Aptinyx’s website.

What is Aptinyx Inc. focused on developing?

Aptinyx Inc. is focused on developing therapies for brain and nervous system disorders using synthetic small molecules.

What are the main product candidates of Aptinyx?

Aptinyx has three clinical product candidates targeting chronic pain, PTSD, and cognitive impairment associated with Parkinson’s disease.

What is the unique mechanism of Aptinyx's drug development?

Aptinyx uses a unique mechanism to modulate NMDA receptors, enhancing synaptic plasticity rather than blocking or over-activating them.